Harrisonia Abyssinica (Harrisonia abyssinica): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does Harrisonia abyssinica work against malaria?

Harrisonia abyssinica contains bioactive compounds including harrisonin and limonoids that demonstrate antimalarial properties through multiple mechanisms. These compounds appear to interfere with Plasmodium parasite development and may inhibit key enzymatic processes necessary for pathogen survival. The plant's terpenoids and flavonoids also contribute antimicrobial and anti-inflammatory effects that support its traditional use. Research on specific mechanisms remains limited (Evidence Level C), with most data derived from in vitro and animal studies rather than human clinical trials.

Does Harrisonia abyssinica interact with antimalarial medications?

No formal drug interaction studies exist for Harrisonia abyssinica (Evidence Level D). However, theoretical concerns arise when combining this herb with prescription antimalarials like artemisinin-based combination therapies. The plant's limonoids and tannins may affect drug metabolism or absorption, potentially altering treatment outcomes. Patients undergoing malaria treatment should avoid concurrent use without medical supervision. The tannin content could also reduce absorption of certain medications if taken simultaneously. Always consult a healthcare provider before combining herbal remedies with prescription drugs.

What is the recommended dosage of Harrisonia abyssinica?

Traditional preparations of Harrisonia abyssinica typically use a root or bark decoction taken as one cup, two to three times daily for adults. This involves boiling approximately 10-15 grams of dried plant material in water. Standardized commercial extracts are not widely available, so dosing varies based on traditional preparation methods. Due to limited clinical research (Evidence Level C), no established therapeutic dose exists. Users should consult qualified traditional medicine practitioners or healthcare providers familiar with East African herbal medicine for guidance.

Is Harrisonia abyssinica safe during pregnancy and breastfeeding?

Harrisonia abyssinica is considered unsafe during pregnancy and should be strictly avoided. Traditional knowledge indicates the herb may stimulate uterine contractions, potentially causing miscarriage. The presence of bioactive limonoids and terpenoids raises additional concerns about embryotoxicity and fetal development. Women who are pregnant, planning pregnancy, or breastfeeding should not use this herb. No human safety studies exist to establish any safe threshold during pregnancy (Evidence Level D). Alternative treatments should be discussed with a qualified healthcare provider.

What are the side effects of Harrisonia abyssinica?

Reported side effects of Harrisonia abyssinica are primarily mild digestive disturbances, including nausea, stomach discomfort, and loose stools. These effects are typically associated with the tannin content and usually resolve after discontinuation. Limited safety data exists beyond traditional use observations (Evidence Level C). No serious adverse events have been documented in ethnobotanical literature, though comprehensive toxicological studies are lacking. Individuals with existing gastrointestinal conditions should use caution. Discontinue use if digestive symptoms persist or worsen.

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 27 PubMed articles · model: gemma4:31b

Summary

Harrisonia abyssinica is a medicinal plant used in traditional medicine across East and West Africa, demonstrating in vitro antibacterial, antifungal, and antiplasmodial activities [PMID:23196018, 19653145, 34867053].

Background

Harrisonia abyssinica is a plant species utilized in traditional healthcare practices in regions including Kenya, Tanzania, Uganda, and Guinea [PMID:35368751, 34867053, 19171185, 17825510].

Traditional uses

It is used as traditional medicine in Tanzania [PMID:34867053] and in Uganda for ethnoveterinary purposes to treat livestock diseases [PMID:19171185]. It is also used in Kenya for the management of bacterial infections [PMID:35368751].

Active compounds

Isolated compounds include steroids such as beta-sitosterol, stigmasterol, campesterol, beta-sitostenone, stigmastenone, campestenone, stigmasta-3,5-dien-7-one, stigmasta-3,5,22-trien-7-one, and campesta-3,5-dien-7-one [PMID:10705738]; limonoids including deoxyobacunone, obacunone, harrisonin, 12beta-acetoxyharrisonin, and pedonin [PMID:11720527]; prenylated acetophenones harronin I and harronin II [PMID:22234410]; tannins chebulagic acid and chebulanin [PMID:25001554]; a cycloterpene called cycloabyssinone and 3-friedelanone [PMID:11395274]; and prenylated polyketides oumarone, bissaone, and aissatone [PMID:10075789].

Mechanism of action

Chebulagic acid and chebulanin isolated from the plant specifically inhibit the calcineurin pathway in Cryptococcus neoformans [PMID:25001554]. Leaf extracts have been shown to modulate neurobehavioral, biochemical, and histopathological activities in aluminum-induced Alzheimer's disease models by affecting hippocampal monoamine and glutamate levels, Bcl2 expression, and inflammatory markers (TNF-α, IL-1β) [PMID:34208063].

Clinical evidence

Evidence DBacterial Infections

Extracts inhibited growth of Staphylococcus aureus, Enterococcus faecium, and Streptococcus uberis (MIC < 1 mg/mL) [PMID:34867053]. Other studies showed activity against Gram-positive and Gram-negative bacteria, though some root extracts showed MIC values ≥ 8 mg/ml [PMID:19057813, 9533435].

Evidence DFungal Infections

Extracts exhibited in vitro antifungal activity [PMID:23196018]; specifically, harronin I showed a MIC of 5 μg/mL against Candida albicans [PMID:22234410] and tannins chebulagic acid and chebulanin showed potent activity against human pathogenic fungi [PMID:25001554].

Evidence DMalaria (Plasmodium falciparum)

Methanolic extracts inhibited Dd2 (IC50 4.7 μg/ml) and 3D7 (IC50 10 μg/ml) strains [PMID:10363837], and root extracts showed antiplasmodial activity [PMID:19653145].

Evidence DAlzheimer's Disease (Animal Model)

Leaf extract ameliorated neurobehavioral, histological, and biochemical changes in the hippocampus of rats with aluminum chloride-induced Alzheimer's disease [PMID:34208063].

Evidence DSchistosomiasis (Animal Model)

An ethanol extract of H. abyssinica proved to be inactive against Schistosoma mansoni in mice [PMID:2497476].

Drug interactions

Ethanolic extracts of Harrisonia abyssinica inhibited the activity of human cytochrome P450 3A subfamily enzymes (CYP3A4, CYP3A5, and CYP3A7) by more than 90% in vitro [PMID:20109542].

Evidence summary

The current evidence consists primarily of in vitro studies and animal models (Level D), demonstrating broad antimicrobial and neuroprotective potential, but lacks human clinical trials.

PubMed sources

1.PMID: 35368751 (2022) — A Systematic Review of Medicinal Plants of Kenya used in the Management of Bacterial Infections. · Evidence-based complementary and alternative medicine : eCAM
2.PMID: 10705738 (2000) — Steroids from Harrisonia abyssinica. · Planta medica
3.PMID: 23196018 (1995) — Biological investigations on Harrisonia abyssinica. · Phytomedicine : international journal of phytotherapy and phytopharmacology
4.PMID: 34208063 (2021) — A Leaf Extract of Harrisonia abyssinica Ameliorates Neurobehavioral, Histological and Biochemical Changes in the Hippocampus of Rats with Aluminum Chloride-Induced Alzheimer's Disease. · Antioxidants (Basel, Switzerland)
5.PMID: 34867053 (2021) — Antimicrobial activities and phytochemical analysis of Harrisonia abyssinica (Oliv) and Vepris simplicifolia (Verd) extracts used as traditional medicine in Tanzania.

Harrisonia Abyssinica

Sources & Citations

Calculate a safe dose of Harrisonia Abyssinica